Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

From Local to International Approach

Prognostic Factors and Treatment Outcomes in Neuroblastoma—A 30-Year Single-Center Retrospective Analysis

Bibliographic Data

ID15716709
AuthorsJoanna Stankiewicz (Nicolaus Copernicus University, corresponding author), Monika Pogorzała (Nicolaus Copernicus University), Piotr Księżniakiewicz (Nicolaus Copernicus University), Jan Styczyński (0000-0002-3158-119X, Nicolaus Copernicus University)
Year2025
Volume12
Issue4
Pages525-525
Publication date2025-04-19
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueChildren (JOURNAL)
Journal identifiersISSN: 2227-9067 • E-ISSN: 2227-9067
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/children12040525
PMID40310212
OpenAlexW4409607294
LanguageEN
References cited28

Background/Objectives : Over the past three decades, significant progress has been made in understanding the biology of neuroblastoma. The integration of prognostic factors has facilitated risk stratification and the development of targeted treatment approaches. This study aims to analyze the outcomes of pediatric patients with neuroblastoma treated at a single oncology center over a 30-year period. Methods : This retrospective study analyzed data from patients aged 0-18 years with neuroblastoma, treated at the Department of Pediatric Hematology and Oncology in Bydgoszcz, Poland, between 1993 and 2023. The study endpoints included the 5-year probability of overall survival (pOS), event-free survival (pEFS), and relapse-free survival (pRFS), analyzed separately for low/intermediate- and high-risk groups. Results : Seventy-five patients met the inclusion criteria. Thirty-two children were categorized as high-risk patients and forty-three as low/intermediate risk. During the study period, outcomes in the low/intermediate-risk group improved significantly (the 5-year pOS 85.7% vs. 100.0%, p = 0.019; the 5-year pRFS 85.7% vs. 100.0%, p = 0.662; the 5-year pEFS 83.3% vs. 100.0%, p = 0.038). In the high-risk group, outcomes improved but did not reach statistical significance (the 5-year pOS 0.0% vs. 41.1%, p = 0.342; the 5-year pRFS 0.0% vs. 32.5%, p = 0.180; and the 5-year pEFS 0.0% vs. 21.5%, p = 0.537). Sixteen patients experienced relapse, of whom only three survived; stem cell transplantation at relapse significantly improved survival (OS 0.0% vs. 50.0%, p = 0.001). In the multivariable analysis, stage at diagnosis was a prognostic factor for pOS (HR 6.0; 95%CI 0.7-49.6, p = 0.096), while pelvic localization was a risk factor for pRFS (HR 3.0; 95%CI 0.8-10.5; p = 0.084). Conclusions : This analysis highlights significant advancements in the diagnosis and treatment of neuroblastoma. Nevertheless, outcomes for high-risk patients and those who experience relapse remain poor, underscoring the need for further therapeutic improvements

Center (category theory · Neuroblastoma · Retrospective cohort study · Single Center · Adrenal and Paraganglionic Tumors · Medicine · Neuroblastoma Research and Treatments · Neurofibromatosis and Schwannoma Cases · Internal Medicine · Oncology

Citation velocityhistorical
Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae